2^nd October at 12:00
Onsite event
in Presidentti auditorium, BioCity

Prof. Makoto Suematsu, Keio University WPI-Bio2Q Research Center
Imaging metabolomics in humanized experimental platforms: Translation to control cancer and neurodegenerative diseases

Host: Bilal Andrabi (sbaand@utu.fi)

Coffee and sandwich at 11:45. First one first serve!

Imaging metabolomics provides multi-dimensional imaging information and includes imaging mass spectroscopy (IMS), surface-enhanced Raman spectroscopy (SERS) and magnetic resonance imaging and spectroscopy (MRI/MRS). Two-dimensional visualization of small molecular metabolites in cancer or ischemic damages by IMS and SERS require rapid frozen protocols to get meaningful interpretation in experimental medicine. We have utilized super-immunodeficient NOG mice which allow engraftment of patient-derived cells or tissues to examine alterations in metabolic systems in vivo by IMS or SERS (1-4). These techniques also benefit clinical application of needle-biopsied or post-operative frozen tissue to predict prognosis of solid cancers (3, 4). We have recently set up imaging metabolomics technology to examine development of patient-derived cancer cells or neural disease models in mice or common marmoset, a non-human primate (5-7): Among them, ultra-high field MRI (UHF-MRI) which enables to chase time history of spatio-temporal alterations in disease regions without euthanasia. I would like to introduce the “humanized” experimental platforms and to discuss how to apply these methods for future collaboration.

Selected publications

Kubo A, et al. Antioxidants (2023)
Paras M, et al. Science (2024)
Yamamoto T, et al. Cancer Research (2024)
Sato K, et al. Lab Animal (2024)

BioCity Turku Guest Seminars are Frontiers of Science -level events with world-famous scientists giving the talks. The speakers are distinguished scientists in their own field of research and they invoke interest among the wide audience. This BioCity Turku Guest Seminar is organized by BioCity Turku, Turku Bioscience Centre and InFLAMES Flagship.